Emcure Pharmaceuticals Ltd (BOM:544210)

Q2 2026 Emcure Pharmaceuticals Ltd Earnings Call Transcript

Nov 11, 2025 / 09:30 AM GMT

Release Date Price: ₹1367.35 (-4.22%)

Transcript

Key Points

Positve

Emcure Pharmaceuticals Ltd (BOM:544210) reported a 13% year-on-year revenue growth, achieving its highest quarterly profits of 251 crores, representing a 25% growth.
The company has partnered with Novo Nordisk to launch a second brand of semaglutide, targeting the obesity market in India, which has significant potential given the large obese population.
The domestic business grew by 10.6% year over year, with strong performance across key segments such as gynecology, cardiology, dermatology, consumer health, and diabetes.
International markets showed robust growth, with Europe experiencing a 22% increase and Canada a 17% rise, driven by market share gains and new product launches.
Emcure Pharmaceuticals Ltd (BOM:544210) is on track to improve its base margins by 150 basis points this year, supported by operating leverage and productivity gains.

Negative

The company's net debt increased to 837 crores due to the partial payoff of an additional stake purchase, delaying its goal to become debt-free by the end of FY26.
There is uncertainty regarding the potential size of the semaglutide opportunity, as the market is still developing and competitive dynamics are yet to be fully understood.
The EBITDA margin has been stable around 19% for several quarters, with limited immediate improvement expected despite ongoing efforts.
The company faces challenges in the ARV segment, with lumpiness in sales and a need for strategic adjustments to maintain growth.
Emcure Pharmaceuticals Ltd (BOM:544210) is reliant on in-licensing deals for growth, which may impact margins and create dependency on external partnerships.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

EMCU.NS - Emcure Pharmaceuticals Ltd
Q2 2026 Emcure Pharmaceuticals Ltd Earnings Call
Nov 11, 2025 / 09:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to MQ Pharmaceuticals Limited Q2 FI26 awnings call. As a reminder, all participant lines will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Piyushnaha.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.